טוען...
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with hydroxyurea resistant or intolerant polycythemia vera (PV) is steadily increasing. Several other JAK2 inhibitors have...
שמור ב:
| הוצא לאור ב: | Blood |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Society of Hematology
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5510786/ https://ncbi.nlm.nih.gov/pubmed/28500170 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-04-742288 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|